HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) A correction has been published Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Maurea, S. Articles by Salvatore, M. Search for Related Content PubMed PubMed Citation Articles by Maurea, S. Articles by Salvatore, M.

Technetium-99m-Tetrofosmin Imaging of Differentiated Mixed Thyroid Cancer

Departments of Nuclear Medicine and Endocrinology, CNR Center for Nuclear Medicine, University Federico II
Department of Nuclear Medicine, National Cancer Institute, Napoli, Italy

Correspondence: For correspondence reprints or contact: Simone Maurea, MD, Via Raffaele de Cesare n. 7, 80132 Napoli, Italy.

ABSTRACT

This report describes the accurate localization of metastatic lesions in a patient with differentiated mixed thyroid cancer using ^99mTc-tetrofosmin imaging. A 66-yr-old women with a cytological diagnosis of follicular thyroid cancer associated with a large amount of goiter changes was studied by ^99mTc-tetrofosmin total-body scintigraphy. No significant tetrofosmin uptake was observed in the thyoid nodules, which mainly showed goiter abnormalities. Abnormal increased tetrofosmin uptake, however, was found in metastatic tumor lesions located in the cervical and dorsal spine as well as in the left lower chest wall and lungs. In conclusion, ^99mTc-tetrofosmin, a new radiopharmaceutical proposed for myocardial perfusion imaging, may be useful in patients with thyroid cancer.

Key Words: technetium-99m-tetrofosmin • total-body imaging • thyroid cancer • metastasis